Fluidless Underwriting Programs That Work: 2026 Examples

The life insurance industry spent years debating whether fluidless underwriting programs could work without degrading mortality experience. That debate is mostly over. Gen Re's 2025 Next Gen Underwriting Survey found that 59% of individual life applications now qualify for an accelerated underwriting path, with 81% of carriers reporting they are meeting their program goals. The remaining question is not whether fluidless works, but which program designs are producing the best results and why.

Gen Re's 2025 Next Gen Analytics study, covering over 14,000 policies and mortality data stretching back to 2019, found that mortality slippage in accelerated underwriting programs has stabilized at approximately 12.3%. That number matters because it represents a manageable, priceable cost of removing fluid requirements from the underwriting process.

What fluidless underwriting actually means in practice

Before looking at specific programs, it is worth clarifying what "fluidless" means in 2026. The term gets used loosely, and the differences between program types matter for mortality outcomes.

Fluidless underwriting eliminates blood and urine testing from the application process. It does not mean eliminating all medical evidence. Most working programs replace lab panels with a combination of electronic health records (EHR), prescription database checks (Milliman IntelliScript or similar), Motor Vehicle Reports, credit-based scores, and increasingly, biometric data captured remotely. The programs that perform well layer multiple data sources rather than relying on applicant self-attestation alone.

Gen Re's survey data breaks this down: of total individual life applications processed in 2024, approximately 12% were eligible for fully automated decisioning, 47% went through accelerated (not fully automated) underwriting, and 41% still followed a traditional path. The fully automated segment is small but growing. The accelerated segment is where most fluidless programs operate.

Carrier programs producing results

MassMutual: Express Path

MassMutual launched its Fluidless Eligible Underwriting Program in August 2024. The program parameters are relatively conservative: ages 17-50, face amounts up to $1 million, standard and better risk classes. It covers all term and individual whole life products including High Early Cash Value (HECV), though Survivorship Whole Life and CareChoice are excluded.

What makes MassMutual's approach notable is the data stack. The company uses its Coverpath digital platform to run applications through electronic health record checks, prescription history, and identity verification before making a fluidless eligibility determination. Applications that do not meet the algorithmic criteria get routed to traditional underwriting automatically. MassMutual's conservative age and face amount limits suggest the company is prioritizing clean mortality experience over volume, which is the right call for a mutual carrier with long-duration liabilities.

Banner Life: expanded accelerated limits

Banner Life increased its accelerated underwriting limit for OPTerm to $4 million effective January 2, 2025. The program covers ages 20-60 and includes a "Lab Lift" feature where electronic health records or an attending physician's statement can substitute for an exam if a complete physical with blood work was completed within 18 months.

The Lab Lift design is worth noting because it captures applicants who already have recent clinical data in the system. Rather than treating fluidless as binary (exam or no exam), Banner Life created a pathway that uses existing medical records as a substitute for new lab work. For applicants with a recent physical, this eliminates redundant testing without reducing the underlying data quality available to underwriters.

Prudential: PruFast Track

Prudential's PruFast Track program routes eligible applicants into one of several underwriting tiers based on the data available. The program uses electronic health data, prescription history, and third-party data sources to build a risk profile, then determines whether an applicant can bypass fluid testing. Prudential has been running accelerated underwriting since before 2020, which means the company has several years of mortality experience to calibrate against.

SBLI: age expansion

SBLI expanded its accelerated underwriting program's eligible age range in February 2025. While the specific parameters vary by product, the expansion signals that SBLI's mortality experience in its existing accelerated cohort has been acceptable enough to widen the aperture. This is the pattern across the industry: carriers that started with narrow eligibility criteria are gradually expanding as their data matures.

Fluidless program comparison across carriers

Carrier	Program name	Age range	Max face amount	Key data sources	Launch / major update
MassMutual	Express Path (Fluidless Eligible)	17-50	$1M	EHR, Rx database, identity verification	August 2024
Banner Life	Accelerated UW (with Lab Lift)	20-60	$4M (OPTerm)	EHR/APS substitute, Rx, MVR	January 2025 (limit increase)
Prudential	PruFast Track	Varies by tier	Varies	EHR, Rx, third-party data	Running since pre-2020, ongoing updates
SBLI	Accelerated UW	Expanded in 2025	Varies by product	Rx, EHR, algorithmic scoring	February 2025 (age expansion)
Lincoln Financial	Professional Advantage	Varies	Up to $20M (with recent physical)	Recent physical exam records, APS	Ongoing

The mortality question: what the data says

The central concern with fluidless underwriting has always been mortality slippage: the difference in mortality experience between fluidless and traditionally underwritten cohorts. If fluidless programs approve applicants who would have been rated or declined under traditional underwriting, the carrier absorbs excess mortality.

Gen Re's Next Gen Analytics study provides the most comprehensive industry data on this question. The 2025 edition, covering policies issued since 2019, found mortality slippage stabilizing around 12.3%. To put that in context: a 12% slippage means that for every $100 of expected mortality in a traditionally underwritten cohort, the fluidless cohort experiences roughly $112. That margin is real, but it is also well within the range that carriers can price for, especially given the operational savings from eliminating paramedical exams.

The 72% of carriers meeting their underwriting goals in Gen Re's survey supports this. Carriers that designed their programs with appropriate guardrails (age limits, face amount caps, multi-source data verification, and robust escalation protocols) are hitting their target mortality ratios. The carriers missing their goals tend to have overly broad eligibility criteria or insufficient data layering.

Tobacco misclassification remains the biggest risk

The single largest source of mortality slippage in fluidless programs is tobacco misclassification. CRL Corp research documented that over 43% of cotinine-positive applicants denied tobacco use on their applications, and tobacco nondisclosure rates increased from 2.0% to 3.5% of applicants between 2015 and 2022. Without fluid verification, carriers rely on prescription database checks and applicant attestation, neither of which catches all tobacco users.

This is where the next generation of fluidless programs diverge. Programs that layer in objective biometric signals, such as cardiovascular data captured through remote photoplethysmography (rPPG) or wearable devices, can partially offset the tobacco verification gap. Resting heart rate and heart rate variability carry independent mortality predictive value, as demonstrated in UK Biobank research covering hundreds of thousands of participants. These signals do not replace cotinine testing, but they provide underwriters with objective physiological data that pure data-pull models lack.

Post-issue auditing: the feedback loop that makes it work

Gen Re's survey found that 86% of carriers plan to implement pre- or post-issue auditing programs. This is arguably the most important operational component of a working fluidless program. Post-issue audits involve randomly sampling approved policies and ordering APS records, running additional verification, or conducting biometric re-measurement to check whether the automated underwriting decision was correct.

The audit feedback loop serves two purposes. First, it catches systematic errors in the underwriting model before they compound into material mortality deviation. Second, it provides the data that reinsurers need to price fluidless business with confidence. Carriers with robust audit programs consistently receive more favorable reinsurance terms than carriers without them.

Munich Re's Biometric Portfolio Analysis platform, which draws on more than 15 years of data from over 30 participating insurers, provides the infrastructure for this kind of calibration. The platform enables carriers and reinsurers to benchmark fluidless program performance against traditional underwriting on a multi-insurer basis, which accelerates the credibility development that individual carriers would need decades to achieve on their own.

What separates programs that work from programs that don't

After reviewing the carrier implementations and mortality data, a few patterns emerge:

• Programs with conservative initial eligibility criteria that expand over time outperform programs that launch with broad eligibility. MassMutual's 17-50 age range and $1M cap is a good example of this approach.
• Multi-source data verification matters more than any single data source. The carriers with the best mortality experience use EHR, Rx databases, MVR, and identity verification in combination, not in isolation.
• Escalation rates are a quality signal. Gen Re's data shows that only 20% of accelerated-eligible applications receive fully automated approval, with 36% approved after human review within the accelerated workflow. Programs that auto-approve too aggressively tend to have worse mortality outcomes.
• Post-issue auditing is not optional. The 86% adoption rate for audit programs reflects an industry consensus that fluidless underwriting requires ongoing calibration.
• Biometric data is the emerging differentiator. Carriers that capture objective physiological measurements at the point of application, whether through rPPG-based camera scanning or other means, are building a data advantage that will compound over time.

Current research and evidence

The evidence base for fluidless underwriting has matured considerably since the early accelerated underwriting pilots of 2016-2018.

Gen Re's longitudinal mortality study, now spanning six years of data, provides the strongest industry-wide evidence that mortality slippage is manageable in well-designed programs. The stabilization at 12.3% slippage suggests that the adverse selection effects of removing fluid testing are bounded rather than compounding over time.

The Society of Actuaries continues to publish mortality studies that include accelerated underwriting cohorts, though the data lags commercial experience by several years. The SOA's work on preferred class mortality differentials has been particularly relevant for carriers trying to maintain best-class distinctions within fluidless programs.

Research from the UK Biobank, a prospective cohort study of approximately 500,000 participants, has provided the epidemiological basis for using cardiovascular signals as underwriting risk factors. Studies published by researchers at the University of Oxford and Imperial College London have demonstrated that resting heart rate, blood pressure, and heart rate variability are independent predictors of all-cause mortality, supporting their use as supplementary data points in fluidless underwriting.

The future of fluidless underwriting

The trajectory is clear: fluidless will become the default pathway for a growing majority of individual life applications. The 59% eligibility rate reported by Gen Re will likely reach 70-75% by 2028 as carriers accumulate more mortality data and expand their eligibility criteria.

The more interesting question is what the data stack will look like. Today's programs rely heavily on third-party data pulls (EHR, Rx, MVR). Tomorrow's programs will increasingly incorporate real-time biometric data captured at the point of application. Companies like Circadify are building the infrastructure for this, enabling carriers to capture vital signs through a smartphone camera scan during the application process. That data layer adds objective physiological measurement to the underwriting file without reintroducing the friction that fluidless programs were designed to eliminate.

The carriers and reinsurers that build the richest data stacks now will have the strongest pricing position as the market shifts. Mortality experience data is a moat, and every month of clean program operation makes that moat wider.

Frequently asked questions

What is the difference between fluidless and accelerated underwriting?

Fluidless underwriting specifically refers to eliminating blood and urine testing. Accelerated underwriting is a broader term that includes any streamlined pathway, which may or may not be fluidless. Some accelerated programs still require labs for certain age or face amount brackets. In practice, the terms overlap significantly, but fluidless is the more specific designation.

How do carriers handle tobacco verification without fluid testing?

Most carriers use prescription database checks to identify nicotine replacement therapy or smoking cessation medications, combined with application attestation. Some programs add biometric signals like heart rate variability. The gap between self-reported and actual tobacco use remains the largest source of mortality slippage, and it is the primary area where new data sources are being layered in.

Are fluidless programs available for high face amounts?

It depends on the carrier. MassMutual caps at $1 million, Banner Life goes up to $4 million for OPTerm, and Lincoln Financial's Professional Advantage program can handle up to $20 million if the applicant has a recent complete physical on file. The general trend is toward higher limits as mortality data matures.

Do reinsurers support fluidless underwriting programs?

Yes. Both Gen Re and Munich Re have published research supporting well-designed fluidless programs and provide pricing frameworks for digitally underwritten business. Reinsurers evaluate programs based on data quality, model governance, escalation protocols, and post-issue audit results. Carriers with strong programs receive favorable treaty terms; carriers with weak data stacks pay higher mortality loads.